Page last updated: 2024-11-06

1-ethyl-2-methyl-3-hydroxypyridin-4-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-ethyl-2-methyl-3-hydroxypyridin-4-one, also known as Deferiprone, is a medication used to treat iron overload in people with thalassemia. It is a chelating agent that binds to iron, helping to remove it from the body. Deferiprone is typically given orally. Common side effects include nausea, vomiting, and abdominal pain. More serious side effects can include neutropenia (low white blood cell count), and agranulocytosis (a severe decrease in white blood cells). Deferiprone is also being studied for its potential use in treating other iron overload conditions, such as hemochromatosis. It is also being studied for its potential use in treating other conditions, such as Alzheimer's disease and cancer.'
```

Cross-References

ID SourceID
PubMed CID94413
CHEMBL ID70110
SCHEMBL ID5525055
MeSH IDM0139809

Synonyms (29)

Synonym
1-ethyl-3-hydroxy-2-methyl-pyridin-4-one
hk-26
4(1h)-pyridinone, 1-ethyl-3-hydroxy-2-methyl-
brn 1449942
cp21 (chelating agent)
1-ethyl-2-methyl-3-hydroxy-pyrid-4-one
1-ethyl-2-methyl-3-hydroxypyridin-4-one
emhp
1-ethyl-3-hydroxy-2-methyl-4(1h)-pyridinone
cp21
CHEMBL70110
FT-0668291
1-ethyl-3-hydroxy-2-methylpyridin-4-one
AKOS006276801
1-ethyl-2-methyl-3-hydroxypyrid-4-one
1-ethyl-3-hydroxy-2-methyl-4-pyridinone
30652-12-1
SCHEMBL5525055
1-ethyl-3-hydroxy-2-methylpyrid-4-one
LCWFIBYPSAWVLI-UHFFFAOYSA-N
1-ethyl-3-hydroxy-2-methylpyridin-4(1h)-one
mfcd01690785
DTXSID60184698
AS-41131
1-ethyl-3-hydroxy-2-methyl-1,4-dihydropyridin-4-one
AB92230
CS-0450703
Z1198157763
EN300-3179940
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID28984Partition coefficient (logD7.4)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID26260Partition coefficient (logD7.4)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
AID96281Tested for growth inhibition against Listeria inocua1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Iron (III)-chelating resins. 3. Synthesis, iron (III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID64554Tested for growth inhibition against Escherichia coli1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Iron (III)-chelating resins. 3. Synthesis, iron (III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands.
AID96282Tested for minimum inhibitory concentration against Listeria inocua1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Iron (III)-chelating resins. 3. Synthesis, iron (III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands.
AID64712Tested for minimum inhibitory concentration against Escherichia coli1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Iron (III)-chelating resins. 3. Synthesis, iron (III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID26251Partition coefficient (logD7.4) for iron(III) complexes1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID99562Tested for iron mobilization from lactoferrin at physiological pH after 24 hours1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Iron (III)-chelating resins. 3. Synthesis, iron (III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands.
AID28931Logarithm of cumulative stability constant was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID26823Acid dissociation constant was determined1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
AID28954Partition coefficient (logP)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID29366Acid dissociation constant (pKa1) was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID26615Acid dissociation constant was determined1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
AID7188Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators.
AID29379Acid dissociation constant (pKa2) was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (23.08)18.7374
1990's7 (53.85)18.2507
2000's2 (15.38)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.99 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]